Fibrosis Analysis
Fibrosis Analysis - Related Videos
09:44
Evaluating Therapeutic Interventions in the SHIP-deficient Mouse Model of Crohn Disease-like Ileitis and Fibrosis
0 Views •
2025
This protocol demonstrates how the Src homology 2 domain-containing 5'-inositol phosphatase (SHIP)-deficient mouse model of Crohn disease (CD)-like ileal inflammation and fibrosis can be used to test novel therapeutics for CD.
09:27
The Dimethylnitrosamine Induced Liver Fibrosis Model in the Rat
0 Views •
Cited by 11 •
2016
We describe a method to produce an animal model of liver fibrosis in the rat, and assess the degree of fibrosis by histological examination of the liver. The model can be used to study the development of liver disease as well as to test the efficacy of potential anti-fibrotic agents.
08:56
Bile Duct Ligation in Mice: Induction of Inflammatory Liver Injury and Fibrosis by Obstructive Cholestasis
0 Views •
Cited by 300 •
2015
Disruption of bile flow results in severe inflammatory cholestatic liver injury with a characteristic time-dependent sequence of morphological alterations. Here we present a protocol for the surgical ligation of the common bile duct in mice that allows to induce a strong fibrotic response after 21 to 28 days.
01:23
Cystic Fibrosis: Pathogenesis
0 Views •
2024
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body. CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
06:26
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
0 Views •
Cited by 1 •
2025
Mouse model of metabolic dysfunction-associated steatotic liver disease (MASLD) with metabolic dysfunction, hepatic gene expression changes, and liver histopathological alterations that resemble human MASLD, including fibrosis that progresses to advanced fibrosis stage 3. This model can be used in studies of MASLD pathophysiology and in pre-clinical studies of new therapies.
FAQs
Fibrosis analysis links persistent injury and inflammation with structural remodeling in affected tissue. By measuring extracellular matrix and collagen accumulation, researchers can examine how activated fibroblasts contribute to altered architecture and potentially impaired organ function. This connection is important because it places quantitative tissue findings within the broader biological progression from ongoing damage to fibrotic remodeling.
The quantity of deposited collagen indicates how extensively connective tissue has accumulated, while its distribution shows where remodeling is concentrated within a tissue section or organ. Considering both features helps distinguish limited from widespread changes and can reveal spatial patterns associated with disease progression. Image-based measurements are therefore useful alongside overall tissue assessment.
These biological factors provide context for interpreting fibrotic measurements. Persistent injury and inflammation are associated with remodeling, while activated fibroblasts contribute to extracellular matrix production and accumulation. A fibrosis analysis can therefore do more than report stained area or molecular signal: it can help characterize how cellular activity and continuing tissue stress correspond to structural change.
Microscopy reveals tissue architecture, collagen distribution, and the location of fibrotic remodeling, whereas biochemical or molecular measurements provide complementary information about tissue composition or biological activity. Combining these approaches strengthens interpretation because a visible structural pattern can be evaluated together with measurable biochemical or molecular changes, rather than relying on a single type of evidence.
A typical workflow examines tissue with an appropriate stain, records microscopic images, and quantifies relevant features in those images. The assessment may then be complemented by biochemical or molecular measurements. Together, these stages determine the extent and distribution of remodeling and create data suitable for evaluating disease-related differences or responses to experimental treatment.
Researchers use fibrosis analysis to characterize disease-associated remodeling, evaluate therapeutic responses, and compare experimental models with clinical samples. The same framework can support questions about how persistent injury or inflammation changes tissue structure and how those changes vary across conditions. Its value lies in producing comparable structural, biochemical, or molecular evidence for these investigations.